

Chimeric Antigen Receptor T-Cell Therapies for B-Cell Cancers: Effectiveness and Value

Key Stakeholder Organizations

ICER has identified the following organizations as key stakeholders for its review of chimeric antigen receptor T-cell (CAR-T) therapies for B-cell cancers. ICER has invited or received input from the following organizations, and welcomes suggestions from the broader community on additional organizations to add to this list. ICER also receives input from independent patients and clinicians, and invites the public to submit recommendations for key stakeholders in these categories.

For a complete list of key dates and opportunities for input on this project, please visit [ICER's website](#).

- Academy of Managed Care Pharmacy
- Aetna, Inc.
- Anthem, Inc.
- American Cancer Society
- American Society for Blood and Marrow Transplant
- American Society for Clinical Oncology
- American Society Pediatric Hematology/Oncology
- American Society for Hematology
- Blue Shield of California
- California Department of Health Care Services
- Children's Oncology Group
- Cancer Support Community
- Cigna, Inc.
- ECOG-ACRIN Cancer Research Group
- Friends of Cancer Research
- Health Net, Inc.
- Kite Pharma
- Leukemia and Lymphoma Society
- Lymphoma Research Foundation
- Novartis AG
- Patients for Affordable Drugs
- Prime Therapeutics
- Premera Blue Cross
- Research Advocacy Network
- UnitedHealthcare Services, Inc.